Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer (PICTURE): a single-arm, multicenter phase 2 trial

BACKGROUND: Patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer and primary resistance to trastuzumab have a poor clinical outcome and lack good evidence to inform clinical decision. This study investigated the efficacy and safety of pyrotinib plus capecitab...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Jun, Teng, Yuee, Li, Huiping, Zhang, Lili, Ouyang, Quchang, Xie, Weimin, Pan, Yueyin, Song, Zhenchuan, Ling, Xiaoling, Wu, Xiaohong, Xu, Jingwei, Li, Li, Ren, Liping, Wang, Hong, Zhou, Dongxian, Luo, Jing, Hu, Xichun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10410905/
https://www.ncbi.nlm.nih.gov/pubmed/37559142
http://dx.doi.org/10.1186/s12916-023-02999-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10410905/
https://www.ncbi.nlm.nih.gov/pubmed/37559142
http://dx.doi.org/10.1186/s12916-023-02999-0

Ejemplares similares